Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates

Antimicrob Agents Chemother. 2020 Nov 17;64(12):e01659-20. doi: 10.1128/AAC.01659-20. Print 2020 Nov 17.

Abstract

Metallo-β-lactamase (MBL)-producing Escherichia coli isolates resistant to the newly developed β-lactam/β-lactamase inhibitor drug combination aztreonam-avibactam (ATM-AVI) have been reported. Here, we analyzed a series of 118 clinical MBL-producing E. coli isolates of various geographical origins for susceptibility to ATM-AVI. The nature of the PBP3 protein sequence and the occurrence of blaCMY genes for susceptibility to ATM-AVI were investigated. We showed here that elevated MICs of ATM-AVI among MBL-producing E. coli isolates resulted from a combination of different features, including modification of PBP3 protein sequence through specific amino acid insertions and production of CMY-type enzymes, particularly, CMY-42. We showed here that those insertions identified in the PBP3 sequence are not considered the unique basis of resistance to ATM-AVI, but they significantly contribute to it.

Keywords: CMY-42; Escherichia coli; NDM; PBP3; aztreonam-avibactam; metallo-β-lactamase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Azabicyclo Compounds
  • Aztreonam* / pharmacology
  • Escherichia coli / genetics
  • Microbial Sensitivity Tests
  • beta-Lactamases* / genetics

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • avibactam
  • beta-Lactamases
  • Aztreonam